Regulus Therapeutics Inc.: stockholders equity

What this measure means

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2009-12-31 to 2024-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Regulus Therapeutics Inc.: total assets
• Regulus Therapeutics Inc.: total liabilities
• Regulus Therapeutics Inc.: cash and cash equivalents
• Regulus Therapeutics Inc.: net income or loss
• Regulus Therapeutics Inc.: operating cash flow
• Regulus Therapeutics Inc.: capital expenditure payments
• Regulus Therapeutics Inc.: revenue
• Regulus Therapeutics Inc.: contract revenue excluding tax
• Regulus Therapeutics Inc.: financing cash flow
• Regulus Therapeutics Inc.: investing cash flow
• Regulus Therapeutics Inc.: retained earnings or deficit
• Regulus Therapeutics Inc.: basic weighted-average shares
• Regulus Therapeutics Inc.: diluted weighted-average shares
• Regulus Therapeutics Inc.: basic earnings per share
• Regulus Therapeutics Inc.: diluted earnings per share
• Regulus Therapeutics Inc.: income tax expense or benefit
• Regulus Therapeutics Inc.: net property, plant and equipment
• Regulus Therapeutics Inc.: share-based compensation expense
• Regulus Therapeutics Inc.: operating income or loss
• Regulus Therapeutics Inc.: current assets
• Regulus Therapeutics Inc.: interest expense
• Regulus Therapeutics Inc.: current liabilities
• Regulus Therapeutics Inc.: current accounts payable
• Regulus Therapeutics Inc.: net finite-lived intangible assets
• Regulus Therapeutics Inc.: operating expenses
• Regulus Therapeutics Inc.: research and development expense
• Regulus Therapeutics Inc.: common shares outstanding
• Regulus Therapeutics Inc.: cash including restricted cash
• Regulus Therapeutics Inc.: additional paid-in capital
• Regulus Therapeutics Inc.: accumulated other comprehensive income or loss
• Regulus Therapeutics Inc.: operating lease right-of-use asset
• Regulus Therapeutics Inc.: operating lease liability
• Regulus Therapeutics Inc.: long-term debt
• Regulus Therapeutics Inc.: gross property, plant and equipment
• Regulus Therapeutics Inc.: accumulated depreciation on property, plant and equipment
• Regulus Therapeutics Inc.: net intangible assets excluding goodwill
• Regulus Therapeutics Inc.: other noncurrent assets
• Regulus Therapeutics Inc.: other noncurrent liabilities
• Regulus Therapeutics Inc.: accrued current liabilities
• Regulus Therapeutics Inc.: prepaid expenses and other current assets
• Regulus Therapeutics Inc.: current contract liabilities
• Regulus Therapeutics Inc.: net deferred tax assets
• Regulus Therapeutics Inc.: pre-tax income or loss from continuing operations
• Regulus Therapeutics Inc.: profit or loss including noncontrolling interests
• Regulus Therapeutics Inc.: comprehensive income or loss
• Regulus Therapeutics Inc.: general and administrative expense
• Regulus Therapeutics Inc.: depreciation, depletion and amortization
• Regulus Therapeutics Inc.: amortization of intangible assets
• Regulus Therapeutics Inc.: current income tax expense or benefit
• Regulus Therapeutics Inc.: deferred income tax expense or benefit
• Regulus Therapeutics Inc.: interest paid, net
• Regulus Therapeutics Inc.: proceeds from issuing common stock
• Regulus Therapeutics Inc.: operating lease payments
• Regulus Therapeutics Inc.: change in accounts payable

Inspect the source

Entity

Regulus Therapeutics Inc. / CIK 0001505512

Captured

2026-09-21T17:19:33.288Z

SEC response SHA-256

d48711811ca317266f22b6dd9aef915292bbf4d32d492a9ca0f457fe5ac78c2d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001505512.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))